Toronto, Ontario - TheNewswire - August 06, 2019 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSXV:VPT) (OTC:VPTDF) is pleased to announce that Dr. Windram and his group of researchers at the Mazankowski Alberta Heart Institute in Edmonton have completed a clinical study on the ability of the VMS+ whole-heart analysis system to analyze 2D echocardiograms of left-ventricle (LV) volumes and ejection fractions (LVEF) without the need for intravenous ultrasonographic enhancing agents. This feasibility study concluded: "The use of the Ventripoint knowledge-based-reconstruction technique revealed no significant differences in the measurement of left ventricular volumes or ejection fraction in comparison with contrast echocardiography measurements."
"This study suggests a routine echocardiogram without contrast-enhancing agents is adequate to determine LV function if analyzed using the VMS+," commented Dr. George Adams, CEO of Ventripoint. "We thank the clinical team for their excellent work in providing the first data on this important application."
The study included 26 patients and found no significant difference between the end-diastolic (LVED) and end-systolic (LVES) ventricular volumes for the left ventricle and LVEF between conventional 2D ultrasound using the VMS+ system and contrast-enhanced ultrasound. Two-dimensional contrast echocardiography has been the standard of care for LV volumes and EF assessment by echocardiography in technically-challenging patients, but the use of contrast comes with added cost and the small risk of anaphylactic reaction. This promising data shows the potential use of the VMS+ in patients who require accurate measurements of LV volumes and LVEF and obviates the need for contrast media to obtain a result.
A copy of the presentation can be viewed on the Ventripoint website at:
Contrast-enhanced echocardiography is warranted on 20% of patients where LV function is required and yet is only used 7% of the time due to technical difficulties (Lindner, J.R., Expert Opinion, posted July 10th, 2017 online at the American College of Cardiology). Contrast echocardiography is increasing in use; however, the procedure requires injecting contrast media into patients. This is uncomfortable, expensive, requires training for intravenous access and takes extra examination time.
The VMS+ is a cost-effective cardiac diagnostic tool measuring whole-heart function in pediatrics and adults with accuracy comparable to MRI. Heart disease is the leading cause of death for both men and women worldwide and having a non-invasive system to obtain volume and ejection fractions for all 4 chambers of the heart is essential for patient care.
About Mazankowski Alberta Heart Institute
The Mazankowski Alberta Heart Institute in Edmonton is a world leader in complex cardiac care and surgery. With a collaborative approach, the team of highly skilled cardiologists, cardiovascular surgeons, cardiac care professionals, researchers and educators are advancing the prevention, detection, treatment and study of cardiovascular disease.
Ventripoint's technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.
For further information please contact:
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release